Prostate Cancer

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

In the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.

Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.

Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.

In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.

“Health literacy pushed people towards active surveillance, which I thought was an interesting finding,” says Adam B. Murphy, MD, MBA, MSCI.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.

Dr Hamstra recommends rectal spacers in certain prostate cancer patients to reduce rectal toxicity, allow dose escalation, and preserve sexual function, but advises judicious use due to potential complications and lack of long-term quality of life data with newer spacers.

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.

The FDA has approved enzalutamide for use with or without a GnRH analog therapy for the treatment of patients with nonmetastatic castration-sensitive prostate cancer.

"I think the main take-home message from our study is that this is a really powerful prognostic prediction tool," says Charles Parker, MD.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.

"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.

“I think the takeaway from the active surveillance [session] is that we've increased the utilization of active surveillance for low-risk appropriate men,” says David S. Morris, MD, FACS.

Analysis of SpaceOAR trial and pooled data found reduced penile bulb radiation dose correlated with better preservation of sexual function over long-term follow-up, suggesting rectal spacers help maintain erectile function in some men with prostate cancer undergoing radiation therapy.

The Phase 3 trials for the Barrigel and BioProtect rectal spacers demonstrated a dosimetric advantage and reduced rectal toxicity similar to SpaceOAR, but data on long-term toxicity and patient-reported outcomes is still needed to fully evaluate the newer spacers.

In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.

"The biggest thing that we're seeing in prostate cancer now, and I think will continue to evolve, is really getting into narrowing our different types and stratifying patients differently," says Benjamin H. Lowentritt, MD, FACS.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

"There are a couple of really exciting directions we want to take this work in," says Charles Parker, MD.

The SpaceOAR rectal spacer phase 3 trial showed reduced toxicity and improved quality of life, leading to FDA approval, but device-related side effects have emerged with broader clinical use.

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term clinical data on patient outcomes.